SAN DIEGO, June 13, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), (Nasdaq: TROVU),a developer of trans-renal molecular diagnostics, announced the full exercise of the over-allotment option granted to the underwriters to purchase 172,500 additional units, at a public offering price of $8.00 per unit, in connection with its previously announced underwritten public offering of 1,150,000 units, bringing total gross proceeds from the offering to $10,580,000.
On June 14, 2012, the holders of the Company's units may elect to separately trade the common stock and warrants underlying the units on The NASDAQ Capital Market under the symbols "TROV" and "TROVW", respectively. The warrants will be exercisable at an exercise price of $5.32 per share upon separation of the units and will expire on June 4, 2017. Those units not separated will continue to trade on The NASDAQ Capital Market under the symbol "TROVU".
Aegis Capital Corp. acted as the sole book-running manager for the offering.
Summer Street Research Partners and Brean Murray, Carret & Co. acted as co-managers for the offering.
A registration statement on Form S-1 relating to the shares was filed with the Securities and Exchange Commission and is effective. Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: firstname.lastname@example.org, or from the above-mentioned SEC website.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.
Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.
SOURCE Trovagene, Inc.